Metastatic Lung Adenocarcinoma Treatment Global Market Report 2025

The metastatic lung adenocarcinoma treatment market size has grown rapidly in recent years. It will grow from$4.13 billion in 2024 to $4.55 billion in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth during the historic period can be attributed to the increasing incidence of lung cancer, the rising demand for targeted therapies, the growing adoption of immunotherapy, higher investments in oncology research, and the increasing awareness about early detection and diagnosis.

The metastatic lung adenocarcinoma treatment market size is expected to see strong growth in the next few years. It will grow to$6.64 billion in 2029 at a compound annual growth rate (CAGR) of 9.9%. The growth during the forecast period can be attributed to the rising prevalence of smoking and environmental factors, the increasing approval of novel drug therapies, the expanding healthcare infrastructure in emerging markets, the rise in personalized medicine approaches, and the growing collaborations between pharmaceutical companies and research institutions. Key trends in the forecast period include advancements in liquid biopsy technologies, the development of advanced combination therapies for better outcomes, innovations in targeted drug delivery systems, progress in AI-driven diagnostics for precision treatment, and the advancement of immuno-oncology treatments.

The increasing adoption of targeted therapy is expected to drive the growth of the metastatic lung adenocarcinoma treatment market. Targeted therapy uses drugs to block cancer growth by targeting specific genes or proteins that drive tumor development and spread. This approach is gaining popularity due to its precision, as it targets specific genetic mutations, resulting in more effective treatment outcomes with fewer side effects compared to traditional therapies. For metastatic lung adenocarcinoma, targeted therapy focuses on blocking genetic mutations that fuel cancer growth, improving survival and quality of life for patients. For instance, in July 2023, the American Society of Gene and Cell Therapy (ASGCT) and Citeline reported that the number of gene therapies in Phase II trials increased by 5%, reaching 260 by the end of Q2 2023. The growing use of targeted therapies is contributing to the market's expansion.

Companies in the metastatic lung adenocarcinoma treatment market are also focusing on developing chemotherapy-free treatments that target specific genetic mutations to improve long-term survival rates and patient outcomes. Chemotherapy-free options, such as targeted therapy and immunotherapy, aim to manage cancer effectively while reducing the harsh side effects of traditional chemotherapy. For example, in August 2024, Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) approved RYBREVANT (amivantamab-vmjw) in combination with LAZCLUZE (lazertinib) as a first-line, chemotherapy-free treatment for metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations. This approval was based on the Phase 3 MARIPOSA study, which showed improved progression-free survival compared to osimertinib.

In January 2024, Bristol Myers Squibb (BMS) acquired Mirati Therapeutics for $4.8 billion to strengthen its cancer treatment portfolio, particularly its targeted therapies for non-small cell lung cancer (NSCLC). The acquisition supports BMS’s strategy to expand its oncology pipeline and address unmet needs in cancer care. Mirati Therapeutics specializes in treatments for KRASG12C-mutated NSCLC, a critical mutation that is difficult to treat. This acquisition enhances BMS’s ability to offer more precise, targeted treatments for lung cancer patients, further propelling the growth of the metastatic lung adenocarcinoma treatment market.

Major players in the metastatic lung adenocarcinoma treatment market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Astellas Pharma Inc., Exelixis, BeiGene Ltd., Novocure, and Blueprint Medicines Corporation.

North America was the largest region in the metastatic lung adenocarcinoma treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in metastatic lung adenocarcinoma treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the metastatic lung adenocarcinoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Metastatic lung adenocarcinoma treatment involves medical strategies aimed at managing lung cancer that has spread beyond the lungs. The primary goals are to slow tumor progression, alleviate symptoms, and prolong survival. As a palliative approach, it focuses on improving the quality of life while controlling the advancement of the disease.

The main types of treatment for metastatic lung adenocarcinoma are chemotherapy, targeted therapy, immunotherapy, and radiation therapy. Chemotherapy uses powerful drugs to kill rapidly dividing cancer cells throughout the body. It is often administered intravenously or orally and can be used alone or in combination with other treatments. The primary routes of administration are oral and intravenous, and the treatment is provided by various end-users, including hospitals, cancer research centers, and specialty clinics.

The metastatic lung adenocarcinoma treatment market research report is one of a series of new reports that provides metastatic lung adenocarcinoma treatment market statistics, including the metastatic lung adenocarcinoma treatment industry global market size, regional shares, competitors with the metastatic lung adenocarcinoma treatment market share, detailed metastatic lung adenocarcinoma treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the metastatic lung adenocarcinoma treatment industry. This metastatic lung adenocarcinoma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The metastatic lung adenocarcinoma treatment market consists of revenues earned by entities by providing services such as palliative and supportive care services, medical oncology services, diagnostic imaging, multidisciplinary team coordination, patient education, and counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The metastatic lung adenocarcinoma treatment market also includes sales of tumor-targeted radiopharmaceuticals, anti-angiogenic agents, and bispecific antibodies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.